HEPATITIS C VIRUS INHIBITORS Russian patent published in 2015 - IPC C07D403/14 A61K31/4184 A61P31/12 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound of formula:

,

wherein: each D and Z is independently absent or represents an optionally substituted linear aliphatic group containing zero to eight carbons, wherein 'aliphatic' refers to an alkyl, alkenyl or alkynyl group, and 'optionally substituted' refers to substituting by replacing independently one, two or more hydrogen atoms by substitutes specified in -F, -Cl, -Br, -I, -OH, -NO₂, -N₃, -CN, -NH₂, -NH-C₁-C₁₂-alkyl, -NH-C₂-C₈-alkenyl, -NH-C₂-C₈-alkynyl, -NH-C₃-C₁₂-cycloalkyl, -dialkylamino, -O-C₁-C₁₂-alkyl, -NHC(O)-C₁-C₁₂-alkyl, -NHC(O)-C₂-C₈-alkenyl, -NHC(O)-C₂-C₈-alkynyl, -NHC(O)-C₃-C₁₂-cycloalkyl; each A and E is independently absent or represents a cyclic group with the above cyclic group is independently specified in a group consisting of aryl or heteroaryl, each of which is optionally substituted; 'aryl' refers to phenyl, naphthyl, tetrahydronaphthyl, indanyl or idenyl; 'heteroaryl' refers to pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl or quinoxalinyl; 'optionally substituted' refers to substituting by replacing independently one, two, three or more hydrogen atoms by substitutes specified by -F, -Cl, -Br, -I, -OH, -NO₂, -N₃, -CN, -NH₂, -NH-C₁-C₁₂-alkyl, -NH-C₂-C₈-alkenyl, -NH-C₂-C₈-alkynyl, -NH-C₃-C₁₂-cycloalkyl, -dialkylamino, -O-C₁-C₁₂-alkyl, -NHC(O)-C₁-C₁₂-alkyl, -NHC(O)-C₂-C₈-alkenyl, -NHC(O)-C₂-C₈-alkynyl, -NHC(O)-C₃-C₁₂-cycloalkyl; T is absent or represents an optionally substituted aliphatic group containing 1 to 24 carbons; 'aliphatic' refers to an alkyl, alkenyl or alkynyl group; 'optionally substituted' refers to substituting substituting by replacing independently one, two, three or more hydrogen atoms by substitutes specified in -F, -Cl, -Br, -I, -OH, -NO₂, -N₃, -CN, -NH₂, -NH-C₁-C₁₂-alkyl, -NH-C₂-C₈-alkenyl, -NH-C₂-C₈-alkynyl, -NH-C₃-C₁₂-cycloalkyl, -dialkylamino, -O-C₁-C₁₂-alkyl, -NHC(O)-C₁-C₁₂-alkyl, -NHC(O)-C₂-C₈-alkenyl, -NHC(O)-C₂-C₈-alkynyl, -NHC(O)-C₃-C₁₂-cycloalkyl; one to four of A, D, E, T and Z are absent; the ring B is specified in imidazolyl, pyrazolyl, 1,3,4-thiazolyl, and 1,3,4-oxadiazolyl, and the ring B is bound to J through atom C and bound to Z, E, T, A and D through atom C; in each specific case, R¹ is independently specified in a group consisting of hydrogen, halogen, cyano optionally substituted by C₁-C₄alkyl, -O-R¹¹, -NR^aR^b, -C(O)R¹¹, -CO₂R¹¹ and -C(O)NR^aR^b; in each specific case, R¹¹ independently represents hydrogen or optionally substituted C₁-C₈alkyl; in each specific case, each R^a and R^b are independently specified in hydrogen, C₁-C₈alkyl and C₂-C₈alkenyl; u is independently equal to 1, 2 or 3; Q and J represent R⁶ is specified in a group consisting of -C(O)-R¹², -C(O)-C(O)-R¹², -S(O)₂-R¹², and -C(S)-R¹²; in each specific case, R¹² is independently specified in a group consisting of -O-R¹¹, -NR^aR^b, and -R¹³; and in each specific case, R¹³ is independently specified in a group consisting of: hydrogen, C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkynyl, C₃-C₈cycloalkyl and C₃-C₈cycloalkenyl, each of which is optionally substituted; 'optionally substituted' refers to substituting independently by replacing one, two, three or more hydrogen atoms by substitutes specified in -F, -Cl, -Br, -I, -OH, -NO₂, -N₃, -CN, -NH₂, -NH-C₁-C₁₂-alkyl, -NH-C₂-C₈-alkenyl, -NH-C₂-C₈-alkynyl, -NH-C₃-C₁₂-cycloalkyl, -dialkylamino, -O-C₁-C₁₂-alkyl, -NHC(O)-C₁-C₁₂-alkyl, -NHC(O)-C₂-C₈-alkenyl, -NHC(O)-C₂-C₈-alkynyl, -NHC(O)-C₃-C₁₂-cycloalkyl, which inhibit an RNA-containing virus, particularly hepatitis C virus (HCV).

EFFECT: preparing hepatitis C inhibitors.

38 cl, 22 tbl, 516 ex